L. Shen et al. / Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 98 (2012) 170–177
171
telecommunications [1–4]. Nevertheless, the Ln(III) complexes
usually give weak luminescence due to the weak absorption coef-
ficient of the parity-forbidden f–f transitions which limits their
practical application considerably. This can be overcome by the
use of high absorbent chelating ligands, which served as efficient
sensitizers. Much work has been done, but the effects on the lumi-
nescence properties of rare-earth complexes still need to be further
studied.
Dimethyl pyridine-2,6-dicarboxylate 1 was prepared by literature
[16]. Other chemicals were of A.R. grade and used without further
purification. The water used in this study was doubly deionized.
Melting points were determined on a XR-4 apparatus (ther-
mometer uncorrected). Elemental analysis was carried out by a
PerkinElmer 2400 elemental analyzer. Infrared spectra (4000–
400 cmꢂ1) were recorded with KBr discs as sample by a Nicolet
NEXUS 670 FT-IR spectrophotometer. 1H NMR was measured with
a Bruker-400 MHz nuclear magnetic resonance spectrometer with
CDCl3, DMSO and D2O as solvents and TMS as internal reference.
The EI-mass spectra were recorded on a Finnigan MAT 90 instru-
ment. UV–Vis spectra were carried out by TU-1800 spectropho-
tometer made by LabTech in Beijing, China. Excitation and
Emission spectra were recorded on a Hitich F-4500 luminescence
spectrophotometer (The width of emission detector slit and the
voltage of photomultiplier tube were 2.5 nm and 700 V respec-
tively for Eu(III) complex; while 5 nm and 400 V for Tb(III) complex
correspondingly in solid state). Thermal gravimetric (TG) were per-
formed in the nitrogen atmosphere using a Netzsch TG 209 ther-
mogravimetric analyzer at a heating rate of 10 °C minꢂ1 from 20
to 700 °C.
Pyridine-2,6-dicarboxylic acid (H2DPC) possesses biological
activity in the body of the animal and plant. Its derivatives and
complexes were studied extensively and were used in all sorts of
fields [5,6]. In the past few years, many studies on the molecular
structure of metal complexes and their biological activities aroused
much interest in the field of inorganic chemistry [7,8]. It was found
that the rare earth metals possessed a special affinity to tumor
cells. For instance, 70% of 169Yb was found to accumulate in tumors
10 min after intravenous injection [9]. Also, the luminescent Eu
and Tb complexes were capable of selectively binding to ‘drug site
II’ of serum albumin and played a significant part in drug pharma-
cokinetics and pharmacodynamics [10]. Serum albumins are the
major soluble protein constituents of the circulatory system and
have many physiological functions. The most important property
of this group of proteins is that they serve as transporters for a
variety of compounds. Therefore, the study of the interactions be-
tween the rare earth metal complexes and serum albumins is
important for the exploration of their biological effects and drug
screening. BSA serves well as protein model for the study due to
its structural homology with human serum albumin (HSA)
[11,12]. Fluorescence spectroscopy is one of the powerful tools to
explore the interaction between the small molecule and bio-mac-
romolecule [13]. Thus, it is useful to study the interactions of the
small molecules and the small molecule complexes with, taking
the quenching of the intrinsic tryptophan fluorescence of BSA as
a tool. The study of the interaction mechanism between drugs or
the small molecules with serum albumins shows great significance
in pharmacokinetics, and it has proved to be one of the most
important research subjects in life science, chemistry and clinical
medicine.
Mostly, many studies focused on the introducing of the coordi-
nation function groups to the H2DPC, resulted in the sensitization
of the rare earth ions [14,15]. Nevertheless, the studies on the
asymmetric ligands containing pyridine-2,6-dicarboxylic acid unit,
are rarely reported. In this paper, a novel asymmetrical chelating
ligands containing pyridine-2,6-dicarboxylic acid unit and their
complexes with Eu(III) and Tb(III) were successfully prepared.
The luminescence spectra of Eu and Tb complexes have been stud-
ied and they were proved to be efficient sensitizers. Moreover, the
interaction mechanism between L, EuL, TbL and BSA were investi-
gated, which was of great importance to understand the general
rules of their interactions and showed the reference value to the
design of new drugs as well. The synthetic route of L was expressed
in Scheme 1.
Preparation of L
Synthesis of 6-(methoxycarbonyl) pyridine-2-carboxylic acid (2)
A solution of 1 (5.85 g, 30.0 mmol) in methanol (150 mL) was
cooled to 0 °C. After KOH pellets (1.76 g, 31.0 mmol) were added,
the reaction mixture was stirred at 0 °C for 2 h and then at room
temperature for 24 h. The solvent was removed under reduced
pressure, and the residue was suspended in H2O (100 mL) and ex-
tracted with ethyl acetate (3 ꢁ 30 mL). The aqueous layers were
acidified to pH 3 with 1 M diluted HCl solution and extracted with
chloroform (5 ꢁ 30 mL). The collected organic layers were dried
over anhydrous Na2SO4. The chloroform was removed in vacuo to
provide the desired product 2 (2.80 g, 52%) as a white solid: m.p.
144–146 °C. 1H NMR (DMSO-d6): dH 8.12–8.24 (m, Py-3,4,5,3H)
3.93 (s, –CH3,3H); 13C NMR(DMSO-d6): d = 52.2, 127.4, 127.7,
139.0, 147.4, 148.9, 164.9, 165.8 ppm; IR (KBr), v/cmꢂ1: 3073,
2964, 2852, 1725, 1581, 1325.
Synthesis of methyl 6-(chlorocarbonyl) pyridine-2-carboxylate (3)
2 (0.72 g, 4 mmol) was treated with thionyl chloride (10 mL)
and one drop of N,N-dimethylformamide, then the mixture was re-
fluxed at 70 °C for 4 h. The excess thionyl chloride was removed by
evaporation under reduced pressure. Residual thionyl chloride was
further removed by co-evaporation with 30 mL of anhydrous ben-
zene to afford the corresponding acid chloride 3. This crude prod-
uct was used in the following step without further purification.
Synthesis of methyl 6-[N,N-bis(methoxycarbonyl methyl)
carbamoyl]pyridine-2-carboxylate (4)
Dimethyl iminodiacetate (0.56 g, 3.5 mmol) and triethylamine
(0.35 g, 3.5 mmol) were dissolved in 15 mL of dichloromethane,
stirring at 0 °C, and then 3 (0.7 g, 3.5 mmol) was added in three
portions with continuous stirring at 0 °C. The reaction mixture
was stirred at room temperature for 1 h. After the solvent was re-
moved under reduced pressure, the residue was dissolved in ethyl
acetate and water (15:15, v:v). The aqueous phase was extracted
with ethyl acetate (2 ꢁ 5 mL). Then, the organic phase was com-
bined and dried by anhydrous Na2SO4. After the solvent was re-
moved under reduced pressure, the crude was further purified by
column chromatography with petroleum ether and ethyl acetate
(1:1) to give 4 (0.9 g, 81.8%) as a white solid: m.p. 80–82 °C. Anal.
Calcd for C14H16N2O7 (%): C, 51.85; H, 4.97; N, 8.64; Found: C,
51.72; H, 4.91; N, 8.62; 1H NMR (CDCl3): d 8.16 (q, J = 7.2 Hz
Py-3,5, 2H), 7.98 (t, J = 8.0 Hz, Py-4, 1H), 4.52 (s, N–CH2, 2H), 4.41
Experimental
Materials and methods
The stock solution of BSA (purity P99%, purchased from Sino-
Biotechnology Company, Shanghai, China) was prepared to be the
concentration of 1.0 ꢁ 10ꢂ5 mol Lꢂ1 by dissolving it in 0.1 M HCl–
Tirs buffer solution (pH 7.4, 50 mM NaCl), and kept it in the dark
at 0–4 °C. After L and its Eu(III) and Tb(III) complexes were dis-
solved in water, and diluted to the desired concentration, the
working solutions of L, Eu(III) and Tb(III) complexes were obtained.
The buffer Tris was purchased from Acros (Geel, Belgium).